

30 November 2006

To all pharmaceutical suppliers, hospital pharmacists, medical groups and interested parties

Consultation on provisional agreement with Schering relating to Postinor, Nuvelle and Progynova

PHARMAC has entered into a provisional agreement with Schering relating to the above products on the Pharmaceutical Schedule. Details of the proposal are outlined below:

Postinor

- Postinor-1 (levonorgestrel 1500 µg tablets) would be listed in Section B of the Pharmaceutical Schedule at a price and subsidy of \$12.50 per tablet as soon as is reasonably practicable following registration.
- Following the listing of Postinor-1, Postinor-2 (levonorgestrel 750 µg tablets) would be delisted from the Pharmaceutical Schedule once current New Zealand stocks are exhausted.
- Postinor-1 and Postinor-2 would be subject to a rebate arrangement between PHARMAC and Schering, and would be protected from tendering until 30 June 2010.
- Postinor-1 would be listed subject to the following restriction:
 - a) Maximum of 2 tablets per prescription

Nuvelle

- PHARMAC would list a new pack size of Nuvelle at the following price and subsidy:

Chemical and strength	Pack size	Price/subsidy
Oestradiol tab 2 mg with levonorgestrel 75 µg (36 tabs) with tab oestradiol 2 mg (48 tabs)	84	\$16.20

Progynova

- The price and subsidy of Progynova (oestradiol valerate) would be reduced from the date of listing of Postinor-1 as follows:

Chemical and strength	Pack size	Current price	Current subsidy	Proposed price/subsidy
Oestradiol valerate tab 1 mg	28	\$5.40	\$4.12	\$4.12
Oestradiol valerate tab 2 mg	28	\$5.40	\$5.40	\$4.12

- PHARMAC would reduce the subsidy on Estrofem (oestradiol tab 2 mg) by reference pricing it to Progynova 2 mg as follows:

Chemical and strength	Pack size	Current price	Current subsidy	Proposed subsidy
Oestradiol tab 2 mg	28 OP	\$7.00	\$5.40	\$4.12

Timing of the above price and subsidy changes would be as follows:

- Following notification by Schering that Postinor-1 has received registration, Postinor-1 would be listed in the Pharmaceutical Schedule as soon as is practicable, allowing for normal Schedule update timelines.
- The price of both strengths of Progynova would be reduced by Schering to \$4.12 per 28 on the 12th day of the month before the listing of Postinor-1, and the subsidy would be amended on the 1st day of the next month.
- The subsidy of Estrofem tab 2 mg would be reduced from the 1st day of the month following the price reduction for Progynova.

If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC by 5:00 pm, 15 December 2006.

Yours sincerely



Sean Dougherty
Therapeutic Group Manager